On May 14, 2024 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET (Press release, Akebia, MAY 14, 2024, View Source/news-releases/news-release-details/akebia-therapeutics-present-2nd-annual-hcw-bioconnect-investor" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-2nd-annual-hcw-bioconnect-investor" rel="nofollow">View Source [SID1234643261]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2nd Annual HCW Bioconnect Investor Conference will take place in New York, NY on May 20, 2024.

A webcast of the presentation can be accessed through the "Investors" section of Akebia’s website at View Source for 30 days following the conference.